bluebird bio (NasdaqGS:BLUE) — Share price, News & Analysis — Simply Wall St


The company was founded as Genetix Pharmaceuticals in April 1992 by MIT faculty members Philippe Leboulch and Irving London.[7]

In 2001, Walter Ogier was appointed Chief Executive Officer of Genetix Pharmaceuticals, and the company was focused on the development of LentiglobinTM for the treatment of sickle cell disease and thalassemia major (beta-thalassemia), the two most globally prevalent severe human genetic diseases.

In September 2010, preliminary results of clinical trials of LentiglobinTM at Hospital Necker in Paris France were published in the journal Nature by Drs. Marina Cavazzana-Calvo and Philippe Leboulch, scientific founder of Genetix Pharmaceuticals / bluebird bio. Stable (21 months) transfusion independence had been successfully achieved by a patient with severe beta-thalassemia who had been treated with Lentiglobin 2 years earlier. This represented the first-ever long term correction of a major human genetic disease by gene therapy. Nature 467, 318–322 (2010)

Also in September 2010, the company was renamed bluebird bio and Nick Leschly was named chief executive officer.[8]

In June 2013, the company became a public company via an initial public offering, raising $116 million.[9]

In June 2014, the company acquired Precision Genome Engineering Inc. for up to $156 million.[10]

In November 2017, Celgene, now Bristol-Myers Squibb (BMS), announced a collaboration with bluebird bio regarding bb2121 Anti-BCMA CAR-T Cell Therapy.[11] In May 2020 the FDA issued a refusal to file letter to BMS and bluebird bio’s marketing application seeking approval of idecabtagene vicleucel (ide-cel) for patients with heavily pre-treated relapsed and refractory multiple myeloma.[12] In September 2020, the FDA accepted bluebird’s marketing application for ide-cel in and established a PDUFA goal date of March 27, 2021.[13] US approval of ide-cel by March 31, 2021 is one of the required remaining milestones of the contingent value rights (CVR) issued upon the close of Bristol Myers Squibb’s purchase of Celgene in 2019. Ide-cel is a BCMA-directed genetically modified autologous CAR-T-cell immunotherapy.

In August 2018, the company announced a collaboration with Regeneron Pharmaceuticals to discover, develop and commercialize new cell therapies for cancer.[14]

On October 8th, 2021 bluebird bio, Inc. announced the impending spinoff of a new public company 2seventy bio focused on oncology. The spin-off is expected to be completed by early November 2021. bluebird bio’s corporate filing announced they have appointed Najoh Tita-Reid and Sarah Glickman to the bluebird bio board of directors. Ms. Glickman will be a member of the board of directors of 2seventy bio and will step down from the bluebird bio board of directors when the new arrangement goes into effect.[15]

Bluebird Bio — факторы роста и падения акций

⚠️ Если вы считаете, что какой-то фактор роста/падения больше не является актуальным, выделите его и нажмите CTRL+ENTER на клавиатуре, чтобы сообщить нам.

Upgrade your FINVIZ experience

Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.

Learn more about FINVIZ*Elite

BLUE Overview

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases and cancer.

bluebird bio Competitors

Price History & Performance

Summary of all time highs, changes and price drops for bluebird bio
Historical stock prices
Current Share Price US$11.31
52 Week High US$53.68
52 Week Low US$10.35
Beta 1.57
1 Month Change -43.17%
3 Month Change -39.94%
1 Year Change -75.13%
3 Year Change -90.29%
5 Year Change -81.03%
Change since IPO -57.97%

Recent News & Updates

Nov 08

bluebird bio (NASDAQ:BLUE) Will Have To Spend Its Cash Wisely

bluebird bio (NASDAQ:BLUE) Will Have To Spend Its Cash Wisely

There’s no doubt that money can be made by owning shares of unprofitable businesses. For example, although…

Nov 03

bluebird bio: Like A Bird In The Middle Of The Deep Blue Sea

bluebird bio was a pioneer in the gene therapy space.Unfortunately, it hasn’t been a commercial success.The upcoming spinoff doesn’t raise confidence in bluebird’s future either.

Shareholder Returns

BLUE US Biotechs US Market
7D -54.5% -7.5% -0.7%
1Y -75.1% 8.4% 28.6%

Return vs Industry: BLUE underperformed the US Biotechs industry which returned 10.7% over the past year.

Return vs Market: BLUE underperformed the US Market which returned 31.1% over the past year.

Price Volatility

Is BLUE’s price volatile compared to industry and market?
BLUE volatility
BLUE Average Weekly Movement 15.4%
Biotechs Industry Average Movement 8.5%
Market Average Movement 5.8%
10% most volatile stocks in US Market 15.1%
10% least volatile stocks in US Market 2.2%

Stable Share Price: BLUE is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: BLUE’s weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases and cancer. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; LentiGlobin for the treatment of sickle cell disease; and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company’s product candidates in oncology include Idecabtagene vicleucel and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma.

bluebird bio Fundamentals Summary

How do bluebird bio’s earnings and revenue compare to its market cap?
BLUE fundamental statistics
Market Cap US$792.91m
Earnings (TTM) -US$864.20m
Revenue (TTM) US$53.65m

Earnings & Revenue

Key profitability statistics from the latest earnings report
BLUE income statement (TTM)
Revenue US$53.65m
Cost of Revenue US$605.49m
Gross Profit -US$551.84m
Expenses US$312.36m
Earnings -US$864.20m

Last Reported Earnings

Sep 30, 2021

Earnings per share (EPS) -12.33
Gross Margin -1,028.58%
Net Profit Margin -1,610.78%
Debt/Equity Ratio 0%

How did BLUE perform over the long term?

See historical performance and comparison


Is bluebird bio undervalued compared to its fair value and its price relative to the market?


Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BLUE’s fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate BLUE’s fair value to establish if it is undervalued.

Price To Earnings Ratio

PE vs Industry: BLUE is unprofitable, so we can’t compare its PE Ratio to the US Biotechs industry average.

PE vs Market: BLUE is unprofitable, so we can’t compare its PE Ratio to the US market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BLUE’s PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: BLUE is good value based on its PB Ratio (0.9x) compared to the US Biotechs industry average (3.1x).


  • Zynteglo: In June 2019, the company received approval from the European Commission to market in the EU betibeglogene autotemcel (Zynteglo), a medication for the treatment of the beta thalassemia group of inherited blood disorders.[16] Bluebird has yet to seek FDA approval for the treatment. The FDA granted Zynteglo orphan drug and breakthrough therapy designations for the treatment of TDT.[16][17][18]

Bluebird Bio — описание компании

Bluebird Bio, Inc., базирующаяся в Кембридже, штат Массачусетс, является биотехнологической компанией, которая разрабатывает генную терапию для лечения тяжелых генетических заболеваний и рака.

Financial Health

How is bluebird bio’s financial position?

Financial Position Analysis

Short Term Liabilities: BLUE’s short term assets ($832.3M) exceed its short term liabilities ($266.6M).

Long Term Liabilities: BLUE’s short term assets ($832.3M) exceed its long term liabilities ($202.6M).

Debt to Equity History and Analysis

Debt Level: BLUE is debt free.

Reducing Debt: BLUE has not had any debt for past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BLUE has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: BLUE has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 23.7% each year.

  • Official website
  • Business data for bluebird bio, Inc.:


What is bluebird bio current dividend yield, its reliability and sustainability?

Dividend Yield vs Market

Notable Dividend: Unable to evaluate BLUE’s dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BLUE’s dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BLUE’s dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BLUE’s dividend payments have been increasing.

Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BLUE’s dividend in 3 years as they are not forecast to pay a notable one for the US market.

Next Steps


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Mr. Nick Leschly has been the Chief Executive Officer and President at bluebird bio, Inc. (alternate name Genetix Pharmaceuticals Inc.) since September 2010. Mr. Leschly served as Interim President at blue

CEO Compensation Analysis

Compensation vs Market: Nick’s total compensation ($USD6.24M) is above average for companies of similar size in the US market ($USD2.19M).

Compensation vs Earnings: Nick’s compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: BLUE’s management team is considered experienced (4.5 years average tenure).

Board Members

Experienced Board: BLUE’s board of directors are seasoned and experienced ( 10.7 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.6%.

Top Shareholders

Company Information

bluebird bio, Inc.’s employee growth, exchange listings and data sources

Key Information

  • Name: bluebird bio, Inc.
  • Ticker: BLUE
  • Exchange: NasdaqGS
  • Founded: 1992
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$792.913m
  • Shares outstanding: 70.11m
  • Website:

Number of Employees


  • bluebird bio, Inc.
  • 60 Binney Street
  • Cambridge
  • Massachusetts
  • 2142
  • United States


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor’s Capital IQ.
Data Last Updated (UTC time)
Company Analysis 2021/11/10 23:28
End of Day Share Price 2021/11/10 00:00
Earnings 2021/09/30
Annual Earnings 2020/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

( 1 оценка, среднее 5 из 5 )
Загрузка ...